Bextra dysmenorrhea (menstural pain) pills
sales and availability

Bextra (Valdecoxib) has proven highly efficient in treating primary dysmenorrhea (severe female menstrual pain) and both osteoarthritis and rheumatoid arthritis. However, Bextra can produce severe even dangerous side-effects in some people, so for senior citizen arthritic conditions we strongly recommend Celebrex instead. In addition we believe Bextra should only be used to treat primary dysmenorrhea only if Tramadol / Ultram has been tried but has not been effective enough.

Bextra Warning
For most women suffering from primary dysmenorrhea, Bextra is a well tolerated and extremely effective pain killer. However, a very small percentage of people will suffer a reaction to this drug and it should be immediately discontinued at the first appearance of skin rash, mucosal lesions, or any other sign of hypersensitivity.

The following Internet pharmacies may sell genuine branded Bextra or generic bextra AKA Valdecoxib or both. Below are the prices, availability and links to the three pharmacies we work with. To understand the processes and benefits of dealing with a pharmacy in the EU or USA, please visit our USA Customers or International Customers pages, depending on where you live.

Yes, the above pharmacies offer different quantity options for Bextra / Valdecoxib primary dysmenorrhea pain relief pills.

Internet Pharmacies 1 & 2 are for everyone; USA & worldwide. They do not require your physician's name / contact data.

Web Pharmacy 3 is for US residents only: please note, under Federal law they may require your physicians name and contact information, and they make be required to contact them.

Bextra was evaluated for treatment of the signs and symptoms of osteoarthritis of the knee or hip, in five double-blind, randomized, controlled trials in which 3918 patients were treated for 3 to 6 months. Bextra was shown to be superior to placebo in improvement in three domains of osteoarthritis symptoms: (1) the Western Ontario and McMaster Universities osteoarthritis index, a composite of pain, stiffness and functional measures in osteoarthritis, (2) the overall patient assessment of pain, and (3) the overall patient global assessment. The two 3-month pivotal trials in osteoarthritis generally showed changes statistically significantly different from placebo, and comparable to the naproxen control, in measures of these domains for the 10 mg/day dose. No additional benefit was seen with a valdecoxib 20-mg daily dose.

Rheumatoid Arthritis
Bextra demonstrated significant reduction compared to placebo in the signs and symptoms of rheumatoid arthritis, as measured by the American College of Rheumatology a composite defined as both improvement of 20% in the number of tender and number of swollen joints, and a 20% improvement in three of the following five: patient global, physician global, patient pain, patient function assessment, and C-reactive protein. Bextra was evaluated for treatment of the signs and symptoms of rheumatoid arthritis in four double-blind, randomized, controlled studies in which 3444 patients were treated for 3 to 6 months. The two 3-month pivotal trials compared valdecoxib to naproxen and placebo.
The results for the ACR20 responses in these trials are shown below (Table 2). Trials of Bextra in rheumatoid arthritis allowed concomitant use of corticosteroids and/or disease-modifying anti-rheumatic drugs, such as methotrexate, gold salts, and hydroxychloroquine. No additional benefit was seen with a valdecoxib 20-mg daily dose.

In 2004 in the USA alone, 6.0 million people were current users of psychotherapeutic drugs taken non-medically (2.5 percent). These include 4.4 million who used pain relievers, 1.6 million who used tranquilizers, 1.2 million who used stimulants, and 0.3 million who used sedatives. It is therefore important to buy effective medications manufactured to strict US FDA and EU regulatory guidelines, such as our pharmacies are constrained to when they offer Bextra / Valdecoxib severe menstrual pain relief pills.